Panel Discussion: Targeting Novel Pathways Beyond IL & JAK Inhibitors to Differentiate Therapies & Expand Treatment Options
- Exploring novel biological pathways beyond established mechanisms, unlocking new therapeutic angles, to differentiate pipelines in a crowded market
- Validating emerging targets with translational data, reducing scientific uncertainty, to increase success rates in development
- Expanding modality and pathway diversity, broadening treatment options, to address unmet patient needs